

RECEIVED  
CENTRAL FAX CENTER

SEP 21 2005



**Patent Technology Centers**

**Facsimile Transmission**

To: Name: central fax  
Company:  
Fax Number: 571-273-8300  
Voice Phone:

From: Name:  
Official Fax Number: (571) 273-8300  
Official After Final Fax Number: (571) 273-8300  
Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

---

---

Date and time of transmission: Wednesday, September 21, 2005 2:26:32 PM  
Number of pages including this cover sheet: 08

---

# Fax Cover Sheet

RECEIVED  
CENTRAL FAX CENTER  
SEP 21 2005



Diagnostics

To: Examiner Taofiq A. Fax 571-273-0709  
Solola

Copies:

From: Marilyn Amick Roche Diagnostics Operations, Inc.  
Tel. (317) 521-7561  
Fax (317) 521-2883

Date: August 29, 2005

No. of pages: 8 (incl. cover sheet)

Re: U.S. Application No.: 10/622,254  
Filed: July 18, 2003  
Inventor(s): Mitali Ghoshal et al.  
Group Art Unit: 1626  
Examiner: Taofiq A. Solola  
Atty Docket No.: RDID02024US

## AMENDMENT FOLLOWING ALLOWANCE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
August 29, 2005
Date of Deposit
Michele Wilson
Name of Person Mailing Correspondence
<u>Michele Wilson</u>
Signature
August 29, 2005
Date of Signature

USPTO  
TO:central fax COMPANY:  
2005-Aug-29 02:10 PM

9/21/2005 2:27 PM PAGE 3/008 Fax Server  
ROCHE DIAGNOSTICS I 3175212883

2/7

**RECEIVED  
CENTRAL FAX CENTER**

**SEP 21 2005**


WEMHH/SB/21 (8/04)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/622,254
		Filing Date	July 18, 2003
		First Named Inventor	Mitali GHOSHAL
		Art Unit	1626
		Examiner Name	Taofiq A. Solola
Total Number of Pages in This Submission	8	Attorney Docket Number	RDID02024US

<b>ENCLOSURES (Check all that apply)</b>			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Allowance <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawings <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <input type="text"/>	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <input type="text"/>	Remarks

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>			
Firm or individual name	Marilyn L. Amick Roche Diagnostics Operations, Inc.		
Signature			
Date	August 29, 2005		

<b>CERTIFICATE OF TRANSMISSION/MAILING</b>			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below			
Typed or printed name	Michele Wilson	Date	August 29, 2005
Signature			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

USPTO 9/21/2005 2:27 PM PAGE 4/008 Fax Server  
TO:central fax COMPANY: 2005-Aug-29 02:11 PM ROCHE DIAGNOSTICS I 3175212883

3/7

**RECEIVED  
CENTRAL FAX CENTER**

Serial No. 10/622,254

RDID 02024

**SEP 21 2005**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: GHOSHAL, Mitali et al.  
Serial No: 10/622,254  
Filed: July 18, 2003  
For: ECSTASY-CLASS DERIVATIVES,  
IMMUNOGENS, AND ANTIBODIES AND THEIR  
USE IN DETECTING ECSTASY-CLASS DRUGS  
Art Unit: 1626  
Examiner: Taofiq A. Solola

**AMENDMENT FOLLOWING ALLOWANCE**

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

August 29, 2005

Dear Sir:

This amendment is being filed in response to the telephone message received by Applicants' representative on August 29, 2005 from Examiner Solola pointing out incomplete paragraphs in the specification that must be completed before the application can be sent to the printers .